Cancers最新文献

{"title":"Impact of Hyaluronic Acid on the Cutaneous T-Cell Lymphoma Microenvironment: A Novel Anti-Tumor Mechanism of Bexarotene.","authors":"Tetsuya Ikawa, Emi Yamazaki, Ryo Amagai, Yumi Kambayashi, Mana Sekine, Takuya Takahashi, Yoshihide Asano, Taku Fujimura","doi":"10.3390/cancers17020324","DOIUrl":"10.3390/cancers17020324","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin's lymphoma that primarily affects the skin, rich in hyaluronic acid (HA). HA is a component of the extracellular matrix in the dermis and likely affects the development of CTCL, but the mechanism is poorly understood. Here we show that low-molecular-weight HA (LMWHA) possibly exacerbates CTCL, and bexarotene, already used in CTCL treatment, decreases HA production.</p><p><strong>Methods: </strong>We conducted immunohistochemistry, qRT-PCR, immunoblotting, and HA quantification using both mouse and human specimens to evaluate the impact of HA on CTCL. Additionally, we assessed the effect of bexarotene, which is already used for CTCL treatment, on HA metabolism.</p><p><strong>Results: </strong>HA expression was higher in patients' serum and skin sections than in healthy controls. HA extracted from the skin of mice inoculated with tumors showed an increase in LMWHA. LMWHA increased lymphoma cell proliferation in vitro and accelerated tumor formation in mice in vivo. LMWHA also created a favorable environment for tumor cells by affecting fibroblasts, vascular endothelial cells, and tumor-associated macrophages. Thus, increased levels of HA, mainly LMWHA, exacerbate CTCL progression by affecting tumor cells and their microenvironment. Bexarotene treatment reduced the amount of total HA in murine tumor-inoculated skin, as well as the supernatant of cultured normal human dermal fibroblasts (NHDFs) and HuT78 cells. Detailed in vitro analyses showed that bexarotene treatment decreased HA synthase (HAS)1 and HAS2 expression in NHDFs and HAS1 and HAS3, and CEMIP expression in HuT78 cells. Chromatin immunoprecipitation assays revealed that bexarotene reduced retinoid X receptor-α binding to the <i>HAS1</i> and <i>HAS2</i> promoters in NHDFs.</p><p><strong>Conclusions: </strong>Bexarotene potentially exerts its anti-tumor effect by reducing HA levels through decreased expression of HAS. These findings provide new insights into the process of CTCL development and additional insights regarding bexarotene treatment.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Physical Exercise on Breast Cancer-Related Lymphedema and Non-Invasive Measurement Tools: A Systematic Review.","authors":"Marta Arias-Crespo, Rubén García-Fernández, Natalia Calvo-Ayuso, Cristian Martín-Vázquez, Maria de Fátima da Silva Vieira Martins, Enedina Quiroga-Sánchez","doi":"10.3390/cancers17020333","DOIUrl":"10.3390/cancers17020333","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Breast cancer-related lymphedema (BCRL) is a chronic disease with lasting effects, making it one of the most feared sequelae of breast cancer with significant personal and social impacts. Therapeutic exercises play a fundamental role in its treatment. This systematic review aims to provide the most up-to-date findings on the impact of physical exercise on the management of BCRL. <b>Methods:</b> Following the PRISMA statement guidelines, searches were conducted in the Web of Science, Scopus, and Science Direct databases. <b>Results:</b> Sixteen studies published between 2019 and 2024 were analyzed in detail. The combination of strength and aerobic exercises emerged as an effective strategy for both the treatment and prevention of lymphedema, also highlighting the innovative potential of virtual reality. <b>Conclusions:</b> It is essential to emphasize tailoring exercise programs to each patient individually. Additionally, the promising role of thermography as a non-invasive and safe tool for evaluating lymphedema progress is underscored.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptional Pathways Predisposing to Cancer Oxidative Stress Sensitivity and Resistance Are Shared Between Hydrogen Peroxide and Cold Gas Plasma but Not Hypochlorous Acid.","authors":"Debora Singer, Sander Bekeschus","doi":"10.3390/cancers17020319","DOIUrl":"10.3390/cancers17020319","url":null,"abstract":"<p><p>Oxidative stress is universal to all cell types, including cancer. It is elicited by a surplus of reactive oxygen species (ROS) or a reduced cellular ability to defend against those. At low levels (oxidative eustress), this induces altered cellular signaling, while at higher levels (oxidative distress), cellular toxicity and non-specific redox signaling become apparent. While oxidation-induced cell death is a hallmark of many cancer therapies, including ROS-producing radiotherapy, some chemotherapies and targeted therapies, photodynamic therapy, and recently emerging physical modalities such as medical gas plasma (a multi-ROS generating technology), less is known about the transcriptional profiles predisposing cancer cells to oxidative demise. In particular, which genes are associated with resistance or sensitivity to ROS overload and subsequent toxicity has not been systematically investigated. Moreover, it is unclear if there are differences between oxidant types, such as hydrogen peroxide and hypochlorous acid. To this end, we here employed 35 cell lines of various origins (e.g., adenocarcinoma, melanoma, leukemia, squamous cell carcinoma, and neuroblastoma). We first performed in-house transcriptomic analysis to assess baseline transcriptional profiles. Second, all cell lines were exposed to four different ROS concentrations of either hydrogen peroxide, hypochlorous, or gas plasma exposure. Third, correlation analysis was performed to identify genes associated with (i) oxidative stress sensitivity, (ii) oxidative stress resistance, and (iii) similarities and/or differences between the different oxidative stress inducers. Intriguingly, distinct gene sets were found for all treatments, and there was a striking difference between hydrogen peroxide and hypochlorous acid, suggesting different modes of action of both oxidants.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton Beam Therapy for Advanced Periocular Skin Cancer: An Eye-Sparing Approach.","authors":"Yingying Zhang, Isabela C S Lima, Alessandra A Woo, Stephen Zieminski, Judith A Adams, Megan A Hughes, Annie W Chan","doi":"10.3390/cancers17020327","DOIUrl":"10.3390/cancers17020327","url":null,"abstract":"<p><p><b>Background/Objectives:</b> The management of periocular skin malignancies presents a unique challenge. Proton beam therapy, due to its sharp dose fall-off, allows for the delivery of a tumoricidal dose to the tumor while sparing adjacent normal tissues. <b>Methods:</b> Thirteen patients with a median age of 76.5 years received protons at our institution to a median dose of 66.6 Gy (RBE). Sixty-four percent of the lesions were basal cell carcinoma, and 22% were squamous cell carcinoma. Eighty-six percent of patients underwent biopsy only or partial resection. Fifty-seven percent of the lesions were located in the medial or lateral canthus. There was orbital invasion in 93% of the cases. Locoregional control probability and overall survival were estimated with the Kaplan-Meier method. Treatment toxicity was scored using the CTCAE 4.0. <b>Results:</b> At a median follow-up of 96 months, there was no local recurrence. The rate of orbital preservation was 100%. Functional vision was maintained in all the patients. There was no acute or late grade 3 or higher toxicity. <b>Conclusions:</b> Protons allow for long-term tumor control with eye preservation in patients with locally advanced periocular skin cancers. Larger prospective multi-institutional trials with standardized ophthalmological assessments are needed to confirm our findings.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Alaei et al. Therapeutic Potential of Targeting the Cytochrome P450 Enzymes Using Lopinavir/Ritonavir in Colorectal Cancer: A Study in Monolayers, Spheroids and In Vivo Models. <i>Cancers</i> 2023, <i>15</i>, 3939.","authors":"Maryam Alaei, Seyedeh Elnaz Nazari, Ghazaleh Pourali, AliReza Asadnia, Mehrdad Moetamani-Ahmadi, Hamid Fiuji, Hamid Tanzadehpanah, Fereshteh Asgharzadeh, Fatemeh Babaei, Fatemeh Khojasteh-Leylakoohi, Ibrahim Saeed Gataa, Mohammad Ali Kiani, Gordon A Ferns, Alfred King-Yin Lam, Seyed Mahdi Hassanian, Majid Khazaei, Elisa Giovannetti, Amir Avan","doi":"10.3390/cancers17020325","DOIUrl":"10.3390/cancers17020325","url":null,"abstract":"<p><p><b>Error in Figure and Text</b> [...].</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the Therapeutic Potential of Algae-Derived Compounds in Hematological Malignancies.","authors":"Tamara Vujović, Tina Paradžik, Sanja Babić Brčić, Roberto Piva","doi":"10.3390/cancers17020318","DOIUrl":"10.3390/cancers17020318","url":null,"abstract":"<p><p>Algae are a rich source of bioactive compounds that have a wide range of beneficial effects on human health and can show significant potential in the treatment of hematological malignancies such as leukemia, lymphoma, and multiple myeloma. These diseases often pose a therapeutic challenge despite recent advances in treatment (e.g., the use of immunomodulatory drugs, proteasome inhibitors, CD38 monoclonal antibodies, stem cell transplant, and targeted therapy). A considerable number of patients experience relapses or resistance to the applied therapies. Algal compounds, alone or in combination with chemotherapy or other more advanced therapies, have exhibited antitumor and immunomodulatory effects in preclinical studies that may improve disease outcomes. These include the ability to induce apoptosis, inhibit tumor growth, and improve immune responses. However, most of these studies are conducted in vitro, often without in vivo validation or clinical trials. This paper summarizes the current evidence on the in vitro effects of algae extracts and isolated compounds on leukemia, lymphoma, and myeloma cell lines. In addition, we address the current advances in the application of algae-derived compounds as targeted drug carriers and their synergistic potential against hematologic malignancies.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining ED90 of Flumazenil for Selective Respiratory Distress Improvement Using Remimazolam During Endoscopic Submucosal Dissection of Gastric Neoplasms: A Prospective Study.","authors":"Hyun Il Kim, Da Hyun Jung, Sung Jin Lee, Namo Kim, Seung Hyun Kim, Yu Jun Ji, Hyo-Jin Byon, Sung Kwan Shin","doi":"10.3390/cancers17020321","DOIUrl":"10.3390/cancers17020321","url":null,"abstract":"<p><strong>Background: </strong>Patients undergoing endoscopic submucosal dissection under monitored anesthesia care (MAC) with remimazolam may develop respiratory distress during the procedure. In these cases, low doses of flumazenil improved respiratory distress without completely reversing sedation, which is a novel phenomenon. This study aimed to explore the ED90 of flumazenil to selectively improve respiratory distress in patients with MAC treated with remimazolam.</p><p><strong>Methods: </strong>Flumazenil dose determination followed a biased-coin up-and-down design. Starting with a dose of 5 mcg, if respiratory distress improved, the biased-coin method was used to give the same dose in the next patient with a probability of 8/9, and a decreased dose of 5 mcg in the next patient with a probability of 1/9. Any improvement in respiratory distress within 30 s of flumazenil administration was recorded. After the procedure, patients were asked whether they had any memory recall during the procedure. Centered isotonic regression was used to determine the ED90 of flumazenil.</p><p><strong>Results: </strong>Sixty patients were included in the study. The estimated ED90 was 76.72 mcg (95% CI: 68.07-102.62). Memory recall occurred in two of thirteen patients (15%) near the ED90 dose range (75 mcg and 80 mcg). None of the patients developed major postoperative complications (bleeding, perforation, or aspiration) within the 2-day postoperative period.</p><p><strong>Conclusions: </strong>This study determined that the ED90 of flumazenil for effectively alleviating respiratory distress in patients undergoing MAC with remimazolam was 76.7 mcg, without reversing consciousness. These findings provide valuable guidance for the care of patients undergoing sedation.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Treatment Toxicity and High Side Effect Burden Among Breast Cancer Survivors: A Retrospective Chart Review.","authors":"Muna Alkhaifi, Elwyn Zhang, Malika Peera, Katarzyna Jerzak, Gregory Czarnota, Andrea Eisen, Amanda Roberts, Carlos Amir Carmona-Gonzalez, Rosanna Pezo, Sonal Gandhi","doi":"10.3390/cancers17020328","DOIUrl":"10.3390/cancers17020328","url":null,"abstract":"<p><strong>Background/objectives: </strong>This study describes the sequelae, side effects, and toxicities experienced by Canadian breast cancer survivors at a breast cancer survivorship clinic at a tertiary academic cancer centre and identifies potential risk factors which may be associated with increased side effect burden.</p><p><strong>Methods: </strong>A retrospective chart review was performed of adult patients treated at the Sunnybrook Breast Cancer Survivorship Clinic from 6 July 2022, to 30 September 2023 (<i>n</i> = 435).</p><p><strong>Results: </strong>Most patients (72.6%) reported at least one side effect impacting their quality of life, and a smaller majority (55.4%) reported two or more side effects. The most common symptoms experienced were anxiety (29.4%), chronic pain (23.9%), hot flashes (21.4%), and fear of recurrence (19.8%). Older age was strongly correlated with a lower likelihood of experiencing greater side effect burden (<i>p</i> < 0.01). Patients who underwent chemotherapy were significantly more likely to experience higher side effect burden than patients who did not. Current smokers were more likely than nonsmokers or past smokers to have a higher burden, for both physical (<i>p</i> < 0.01) and psychological side effects (<i>p</i> < 0.01). The multivariate analysis demonstrated that younger age was strongly associated with greater side effect burden, higher likelihood of psychological and physical symptoms, and greater likelihood of requiring close follow-up.</p><p><strong>Conclusions: </strong>The results highlight the need for survivorship resources tailored to survivors under the age of 55 and the importance of referring smokers to smoking cessation programs. Additional research is required to explore the significant reluctance among patients regarding discharge. Future studies should examine the acute needs of younger breast cancer survivors and investigate the impact of smoking and treatment modalities on the side effect burden.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the Progression from Asymptomatic to Symptomatic Multiple Myeloma and Stage Classification Using Gene Expression Data.","authors":"Nestoras Karathanasis, George M Spyrou","doi":"10.3390/cancers17020332","DOIUrl":"10.3390/cancers17020332","url":null,"abstract":"<p><strong>Background: </strong>The accurate staging of multiple myeloma (MM) is essential for optimizing treatment strategies, while predicting the progression of asymptomatic patients, also referred to as monoclonal gammopathy of undetermined significance (MGUS), to symptomatic MM remains a significant challenge due to limited data. This study aimed to develop machine learning models to enhance MM staging accuracy and stratify asymptomatic patients by their risk of progression.</p><p><strong>Methods: </strong>We utilized gene expression microarray datasets to develop machine learning models, combined with various data transformations. For multiple myeloma staging, models were trained on a single dataset and validated across five independent datasets, with performance evaluated using multiclass area under the curve (AUC) metrics. To predict progression in asymptomatic patients, we employed two approaches: (1) training models on a dataset comprising asymptomatic patients who either progressed or remained stable without progressing to multiple myeloma, and (2) training models on multiple datasets combining asymptomatic and multiple myeloma samples and then testing their ability to distinguish between asymptomatic and asymptomatic that progressed. We performed feature selection and enrichment analyses to identify key signaling pathways underlying disease stages and progression.</p><p><strong>Results: </strong>Multiple myeloma staging models demonstrated high efficacy, with ElasticNet achieving consistent multiclass AUC values of 0.9 across datasets and transformations, demonstrating robust generalizability. For asymptomatic progression, both modeling approaches yielded similar results, with AUC values exceeding 0.8 across datasets and algorithms (ElasticNet, Boosting, and Support Vector Machines), underscoring their potential in identifying progression risk. Enrichment analyses revealed key pathways, including PI3K-Akt, MAPK, Wnt, and mTOR, as central to MM pathogenesis.</p><p><strong>Conclusions: </strong>To the best of our knowledge, this is the first study to utilize gene expression datasets for classifying patients across different stages of multiple myeloma and to integrate multiple myeloma with asymptomatic cases to predict disease progression, offering a novel methodology with potential clinical applications in patient monitoring and early intervention.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urogenital Cancer Epidemiology in Poland (1980-2020): A Narrative Review.","authors":"Iwona Wnętrzak, Joanna Didkowska, Roman Sosnowski, Mateusz Czajkowski, Dawid Sigorski, Bartosz Małkiewicz, Piotr Marczyński, Jarosław Jaskulski, Piotr Kania, Adam Ostrowski, Artur Sieczych, Grzegorz Kade, Piotr Purpurowicz, Stanisław Szempliński, Robert Nowakowski","doi":"10.3390/cancers17020316","DOIUrl":"10.3390/cancers17020316","url":null,"abstract":"<p><p>Despite advances in prophylaxis, early diagnosis, and treatment, urogenital cancers represent a significant challenge to public health in Poland due to their relatively high prevalence and mortality rates. This narrative review aims to explore contemporary evidence on the epidemiology of urogenital cancers in Poland, such as prostate cancer, bladder cancer, kidney cancer, testicular cancer, and penile cancer, focusing on current and historical status and trends in the broader context of healthcare delivery. The literature consistently indicates that urogenital cancer continues to be a significant contributor to cancer incidence and mortality rates in Poland. Although the body of evidence is expanding, its quantity remains limited, primarily attributable to the scarcity of top-notch epidemiological investigations targeting particular forms of cancer, such as testicular and penile cancers, which are characterized by sporadic occurrences.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}